TRANSTHERA-B (02617) published in the sub-journal of Nature, exploring the preliminary clinical results of the core product Tengotinib and combination with Atizumab in the treatment of advanced solid tumors.

TRANSTHERA-B (02617) announced the exploratory clinical results of the core product Tenogetto Nib in combination with the anti-angiogenesis drug Atelizumab for the treatment of advanced solid tumors in Nature Communications (IF=15.7). Tenogetto Nib is a kinase spectrum-selective multi-kinase inhibitor that targets fibroblast growth factor receptors 1-3 (FGFR1-3), Janus kinases 1/2 (JAK1/2), vascular endothelial growth factor receptors (VEGFRs), and Aurora kinases A/B (Aurora A/B). The phase Ib/II clinical trial conducted in China (trial number: NCT05253053) evaluated the efficacy of Tenogetto Nib monotherapy (Group A, 53 patients with advanced solid tumors) and the combination of Atelizumab monotherapy (Group B, 31 patients with advanced biliary system tumors). The objective response rate (ORR) of Tenogetto Nib monotherapy in Group A was 16.7%, while the ORR of the combination of Atelizumab in Group B was 22.6%, both demonstrating anti-tumor activity. In the pre-specified exploratory subgroup analysis, significant efficacy was observed in patients with bile duct cancer, with an ORR of 30.8% in Group A (n=13) and 25.0% in Group B (n=28). For patients with bile duct cancer who had progressed after previous treatment with FGFR inhibitors and carried FGFR2 fusion mutations, the ORR of Tenogetto Nib monotherapy was 66.7%. Among 20 patients with bile duct cancer who had previously received immune checkpoint inhibitors, the combination therapy showed an ORR of 20.0% and a disease control rate of 75.0%. These results support further advancement of Tenogetto Nib monotherapy and combination immunotherapy in clinical development.